HDM2021 / Huadong Medicine - LARVOL DELTA

HDM2021, a potent and selective CBL-B inhibitor exhibits robust immunomodulatory efficacy for anti-tumor therapy (AACR 2026) - "HDM2021 has demonstrated potent CBL-B inhibition and robust efficacy in both in vitro and in vivo models. It also exhibits improved pharmacokinetic properties, high target selectivity, and a favorable safety profile. These findings support its further development as a novel immunomodulatory drug candidate for anti-tumor therapy."

Clinical • Immunomodulating • Hematological Malignancies • Lymphoma • Oncology

Discovery of HDM2021 as a Highly Potent CBL-B Inhibitor for Cancer Treatment (SITC 2025) - "These findings strongly support HDM2021 a novel immunomodulatory drug candidate for anti-tumor therapy. IND-enabling studies have been started for INDs application."

Hematological Malignancies • Lymphoma • Oncology • IFNG